23andMe DNA Test Kit Service Options

23andMe® offers several service options to choose from. All services require submitting a saliva sample using our saliva collection kit that you send to our lab for analysis.

You should choose the service option that’s right for you:

• The Health + Ancestry Service includes all of the reports and features offered in the Ancestry Service (outlined below) plus reports on Carrier Status*, Health Predisposition*, and Wellness. Customers who purchase the Ancestry Service will have the option to upgrade to the Health + Ancestry Service later for an additional fee.

• The Ancestry Service and the Health + Ancestry Service include features to explore how your DNA connects you to other people. For example, if you choose to participate in the DNA Relatives feature, we can compare your DNA to other 23andMe customers, find your genetic matches, and estimate how closely you are related. The Health Service does not include these features.

• The 23andMe+ Membership includes everything from the Health + Ancestry Service, as well as access to exclusive reports to help customers learn about their heart health, how they process certain medications**, migraines, and more. Learn more about 23andMe+.

• The Health Service includes reports on Carrier Status*, Health Predisposition*, and Wellness. At this time, the Health Service can only be purchased through Amazon or through FSAStore.com / HSAStore.com. Customers who purchase this service option may be fully eligible for FSA/HSA reimbursement.

• The 23andMe+ Total Health membership offers all of the features and reports provided in our 23andMe+ Membership, plus exome sequencing, bi-annual blood testing, and direct access to clinicians with unique knowledge and training in genetics-informed care. Members will get personalized recommendations focusing on ongoing disease prevention and early detection.

For more information about the services we offer, please click on any of the options below:

*The 23andMe PGS test includes health predisposition and carrier status reports. 23andMe health predisposition reports include both reports that meet FDA requirements for genetic health risks and reports which are based on 23andMe research and have not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child's risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. For important information and limitations regarding each genetic health risk and carrier status report, visit 23andme.com/test-info/.

**23andMe PGS Pharmacogenetics reports: The 23andMe test uses qualitative genotyping to detect 3 variants in the CYP2C19 gene, 2 variants in the DPYD gene and 1 variant in the SLCO1B1 gene in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic and does not describe the association between detected variants and any specific therapeutic. Our CYP2C19 Pharmacogenetics report provides certain information about variants associated with metabolism of some therapeutics and provides interpretive drug information regarding the potential effect of citalopram and clopidogrel therapy. Results for SLCO1B1 and DPYD and certain CYP2C19 results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For important information and limitations regarding Pharmacogenetics reports, visit 23andme.com/test-info/pharmacogenetics/.

***This data has undergone a general quality review however only a subset of markers have been individually validated for accuracy. The data from 23andMe’s Browse Raw Data feature is suitable only for informational use and not for medical, diagnostic or other use. Consult with a healthcare professional before making any major lifestyle changes.